Category:
Description:
Indications:
-
PO:
PVC’s, ventricular tachycardia (when not associated with complete
heart block), junctional (nodal) dysrhythmias, AV junctional premature
complexes, paroxysmal junctional tachycardia, premature atrial
contractions, paroxysmal atrial tachycardia, atrial flutter, atrial
fibrillation (chronic and paroxysmal)
-
IM/IV:
when PO therapy not feasible or when rapid therapeutic effect is
required, life threatening Plasmodium
falciparum malaria
Contraindications:
-
Digitalis
intoxication manifested by AV conduction disorders, complete AV block
with an AV nodal or idioventricular pacemaker, left bundle branch
block, or other severe intraventicular condition defects with marked
QRS widening, ectopic impulses, and abnormal rhythms due to escape
mechanisms, history of drug-induced torsade de pointes, history of
long QT syndrome, myasthenia gravis
Precautions:
-
Pregnancy
category C; use during pregnancy considered safe for the fetus; high
doses can produce oxytocic properties and potential for abortion;
excreted in breast milk; compatible with breast feeding
-
Treatment
of atrial flutter without prior medication to control ventricular rate
-
Marginally
compensated cardiovascular disease, incomplete AV block
-
Digitalis
intoxication, hyperkalemia, renal, or hepatic insufficiency
Adverse
Reactions (Side Effects):
-
CNS:
apprehension, ataxia, confusion, delirium, dementia, depression,
dizziness, excitement, fever, headache, vertigo
-
CV:
angioedema, arterial embolism, bradycardia, complete AV block,
hypotension, prolonged QT interval, syncope, torsade de pointes,
ventricular extrasystoles, ventricular flutter, ventricular
tachycardia and fibrillation, widening of the QRS complex
-
EENT:
disturbed hearing, disturbed vision, optic neuritis, reduced visual
field
-
GI:
abdominal pain, diarrhea, esophagitis, hepatotoxicity, nausea,
vomiting
-
HEME:
acute hemolytic anemia, agranulocytosis, leukocytosis, neutropenia,
thrombocytopenic purpura
-
MS:
arthralgia, increase in serum skeletal muscle creatine phosphokinase,
myalgia
-
SKIN:
abnormalities of pigmentation, cutaneous flushing with intense
pruritus, eczema, exfoliative eruptions, photosensitivity, psoriasis,
purpura, rash, urticaria, vasculitis
-
MISC:
cinchonism, lupus nephritis, positive ANA, systemic lupus
erythematosus
|
Dosage:
Administered
orally
-
Adult: Give 200mg test dose PO/IM (gluconate) several hours before
full dosage to determine possibility of idiosyncratic reaction: PO
10-600mg every 4-6 hours, initiate at 200 mg/dose and adjust dose to
maintain desired therapeutic effect, max 3-4g daily; SUS REL 300-600mg
every 8-12 hours;
-
Child: Give 2 mg/kg test dose PO/IM (gluconate) several hours before
full dosage to determine possibility of idiosyncratic reaction: PO
15-60 mg/kg/day divided into 4-5 doses or 6 mg/kg every 4-6 hours;
usual 30 mg/kg/day or 900mg per square meter daily given in 5 divided
doses
|
The information contained here is an abbreviated summary. For more detailed
and complete information, consult the manufacturer's product information sheets
or standard textbooks.
Source:
Operational Medicine 2001, Health
Care in Military Settings, NAVMED P-5139, May 1, 2001, Bureau
of Medicine and Surgery, Department
of the Navy, 2300 E Street NW, Washington, D.C., 20372-5300
OB-GYN 101:
Introductory Obstetrics & Gynecology
© 2003, 2004, 2005, 2008
Brookside Associates, LLC
All rights reserved
|